2022-07-22-港交所-天大药业_2022年报_166页_4mb

2022 Annual Report Summary

Core Content Overview

This summary outlines the key information and main points from the 2022 Annual Report of Tianda Pharmaceuticals Limited, including corporate structure, director profiles, strategic initiatives, financial performance, and future outlook.

Main Points

Corporate Information

• Company Name: Tianda Pharmaceuticals Limited
• Registered Office: Cricket Square, Hutchins Drive, P.O.Box 2681, Grand Cayman, Cayman Islands
• Place of Listing: The Stock Exchange of Hong Kong Limited
• Stock Code: 00455
• Corporate Website: www.tiandapharma.com

Board of Directors

• Executive Directors:
  • Mr. Fang Wen Quan (Chairman and Managing Director)
  • Mr. Lui Man Sang
• Non-Executive Directors:
  • Mr. Shen Bo
  • Mr. Feng Quanming
  • Dr. Lam Lee G. (retired on 26 August 2021)
• Independent Non-Executive Directors:
  • Mr. Lam Yat Fai
  • Mr. Chiu Sung Hong
  • Mr. Chiu Fan Wa

Key Committees

• Audit Committee: Mr. Lam Yat Fai (Chairman), Mr. Chiu Sung Hong, Mr. Chiu Fan Wa, Mr. Shen Bo
• Remuneration Committee: Mr. Chiu Sung Hong (Chairman), Mr. Fang Wen Quan, Mr. Lam Yat Fai, Mr. Chiu Fan Wa
• Nomination Committee: Mr. Fang Wen Quan (Chairman), Mr. Lam Yat Fai, Mr. Chiu Sung Hong
• Risk Management Committee: Mr. Chiu Sung Hong (Chairman), Mr. Fang Wen Quan, Mr. Lam Yat Fai

Auditor and Legal Advisor

• Auditor: Ernst & Young, Certified Public Accountants, Registered Public Interest Entity Auditor
• Hong Kong Legal Advisor: Woo, Kwan, Lee & Lo

Company Secretary

• Mr. Lo Tai On

Principal Bankers

• Bank of Communications
• Industrial and Commercial Bank of China
• China Merchants Bank
• Bank of China
• Agricultural Bank of China

Financial Performance

Revenue

• Total Revenue (FYE2022): HK$510.0 million
• Increase from FYE2021: HK$35.7 million or 7.5%

Business Segments

• Pharmaceuticals and Medical Technologies:

  • Revenue (FYE2022): HK$396.1 million
  • Increase from FYE2021: HK$38.4 million or 10.7%
  • Key Product: Tuoping® Valsartan capsules, which became the top-selling product in its category in China
  • New R&D and Production Base: Successfully launched in Zhuhai, signed 5 CDMO/CMO contracts

• Chinese Medicine Business:

  • Revenue (FYE2022): HK$106.5 million
  • Decrease from FYE2021: HK$5.5 million or 4.9%
  • Reason for Decrease: Impact of the pandemic on transportation and production

• Medical and Healthcare Services:

  • Revenue (FYE2022): HK$7.4 million
  • Increase from FYE2021: HK$2.7 million or 57.4%
  • Key Initiatives:
    • Launch of "TDMall on Cloud" platform
    • "Free Consultation and Medicine" charity campaign
    • Expansion of TDMall in Zhuhai, Hong Kong, and Sydney

R&D and Innovation

• R&D Expenses (FYE2022): HK$15.9 million
• Increase from FYE2021: HK$4.1 million or 34.7%
• Recent Developments:
  • Completed consistency evaluation for Ibuprofen suspension
  • Conducted material benchmark studies for three classic prescriptions
  • Accelerated R&D of innovative Chinese medicine products
  • Completed pilot and pre-BE studies for Montelukast Sodium Granules
  • Completed pharmacological trials and pre-pilot tests for Nicorandil for injection
  • Three small-molecule food peptide products developed, produced, and launched
  • Accelerated development of cosmetics peptide series

Strategic Initiatives

• "Three Developments" Strategy:

  • Develop Chinese medicine business as the foundation
  • Develop innovative drugs and medical technologies
  • Develop quality medical and healthcare services

• "3D+1S" Initiatives:

  • Business Development (BD)
  • Research and Development (R&D)
  • Investment and Development (ID)
  • Marketing & Sales (S)

• Expansion Plans:

  • Focus on expanding in the Greater Bay Area
  • Plans for national and global rollout
  • Emphasis on mergers and acquisitions, external introduction, and internal R&D

Awards and Certifications

• Outstanding Brand Awards 2021: Chinese Medicine Services
• "TDMall on Cloud" App: Won the Hong Kong Business Technology Excellence Awards 2021 - Mobile (Healthcare Technology)
• SGS ISO 9001:2015 Certification: Zhuhai TDMall
• Qualicert Service Quality Certification: Zhuhai TDMall
• Information System Security Protection Certification (Level 3): "TDMall on Cloud" App
• "Best Mid and Small Caps Company" Award: Won for two consecutive years

Corporate Governance

• The Group maintains a robust governance structure with various committees overseeing different aspects of operations.
• The Board of Directors is composed of a mix of executive and independent non-executive directors, with clear roles and responsibilities.
• The Group is committed to corporate governance and has a strong emphasis on transparency and accountability.

Future Outlook

• The Group remains optimistic about the long-term development of the medical industry, particularly the Chinese medicine sector.
• The "14th Five-Year Plan" and the Healthy China Initiative provide a favorable macro environment for the medical and healthcare industry.
• The Group plans to deepen its layout in the three business segments, improve operational efficiency, accelerate product introduction and R&D, and strengthen business expansion and investment development.
• The objective is to become a leading pharmaceutical enterprise with a strong presence in China and expanding globally.

Conclusion

The Group has made steady progress and achieved high-quality development in the FYE2022, with a total revenue increase of 7.5%. The strategic focus on Chinese medicine, innovation, and quality healthcare services, along with the implementation of the "3D+1S" initiatives, has driven growth and expansion. The Group is well-positioned to leverage the favorable macro environment and continue its development path towards becoming a leading player in the global pharmaceutical industry.